![]() |
Technical Data |
|
T5050-06A |
Thrombopoietin, Recombinant, Mouse (TPO, Mpl-ligand, MGDF) |
2ug 10ug |
| Molecular Biology | Storage: -20°CShipping: Blue Ice |
|
Thrombopoietin (TPO) is a lineage specific growth factor, produced in the liver, kidney and skeletal muscle. It stimulates the proliferation and maturation of megakaryocytes, and promotes increased circulating levels of platelets in vivo. TPO signals through the c-mpl receptor and acts as an important regulator of circulating platelets. Human and murine TPO exhibits cross-species reactivity. Recombinant murine TPO is a fully biologically active 174 amino acid polypeptide (18.7kD), which contains the erythropoietin-like domain of the full length TPO protein. This comprises the receptor binding domain of the Mpl-ligand protein. AA Sequence: SPVAPACDPR LLNKLLRDSH LLHSRLSQCP DVDPLSIPVL LPAVDFSLGE WKTQTEQSKA QDILGAVSLL LEGVMAARGQ LEPSCLSSLL GQLSGQVRLL LGALQGLLGT QLPLQGRTTA HKDPNALFLS LQQLLRGKVR FLLLVEGPTL CVRRTLPTTA VPSSTSQLLT LNKF Biological Activity: The ED50 as determined by the dose-dependent stimulation of the proliferation of human MO7e cells was found to be < 1ng/ml, corresponding to a speci c activity of 1x10e6u/mg. Storage and Stability: Lyophilized powder may be stored at 4°C for short-term only. Reconstitute to nominal volume by adding sterile buffer. Aliquot and store at -20°C. Reconstituted product is stable for 12 months at -20°C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer. Country of Origin: USA |
Source: Murine, recombinant (E. coli). Purity: 98% (SDS-PAGE and HPLC) Endotoxin: 0.1ng/ug (1EU/ug). Form: Supplied as a lyophilized powder in 10mM Tris, pH 8.0. Reconstitution: Reconstitution in water to a concentration of 0.5-1mg/ml. Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications without the expressed written authorization of United States Biological. |
|
1. Klarmann, K., Identification of in vitro growth conditions for c-Kit-negative hematopoietic stem cells. Blood 102(9): 3120-3128 (11/1/2003).
|
||